DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Acute Myeloid Leukemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Myeloid Leukemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Myeloid Leukemia: An Overview
Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. AML can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other parts of the body.
The most prevalent form of leukemia in adults is AML, which makes up around 80% of all cases. It is characterized by ineffective erythropoiesis and bone marrow failure is caused by clonal growth of immature “blast cells” in the peripheral blood and bone marrow. AML is the most common acute leukemia in adults and primarily affects older people with a median age of diagnosis of ~67 years. The chromosomal anomalies that each patient possesses are often exclusive to them. The frequency of anomalies is greater as people age.
Acute Myeloid Leukemia Market Key Facts
-
AML is one of the most common types of leukemia in adults. Still, AML is fairly rare overall, accounting for only about 1% of all cancers.
-
According to Cancer Research UK, AML incidence is strongly related to age, with the highest incidence rate being in older people. In the UK in 2016-2018, on average each year, more than 4 in 10 new cases (42%) were in people aged 75 and over. Age-specific incidence rates rise gradually from birth, rise steadily from around age 50-54, rise more steeply from age 60-64, and drop in the oldest age groups.
-
As per the study by Miyamoto & Minami (2019), the annual incidence of AML in Japan is 5.6 per 100,000.
-
According to data from a report titled, “Global Burden of Disease Study”, by the Institute for Health Metrics and Evaluation (2018), in 2017, among the EU5 countries, the UK had the highest prevalence of AML, at more than 5,000 cases, while Spain has the lowest at under 2,300 cases.
-
According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of acute myeloid leukemia was 4.3 per 100,000 men and women per year in the United States.
-
As per DelveInsight’s analysis, acute myeloid leukemia (AML) is more prominent in males in comparison to females.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Myeloid Leukemia pipeline therapies. It also thoroughly assesses the Acute Myeloid Leukemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Acute Myeloid Leukemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Myeloid Leukemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Acute Myeloid Leukemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Myeloid Leukemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Acute Myeloid Leukemia Epidemiology, Segmented as –
-
Total Incident Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)
-
Gender-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)
-
Age-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)
-
Mutation-specific Cases of Acute Myeloid Leukemia in the 7MM (2019–2032)
Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Myeloid Leukemia market or expected to be launched during the study period. The analysis covers the Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acute Myeloid Leukemia drugs based on their sale and market share.
The report also covers the Acute Myeloid Leukemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Myeloid Leukemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Myeloid Leukemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market
Acute Myeloid Leukemia Therapeutics Analysis
The goal of treatment is remission. Current conventional therapeutic options for AML rely on intensive chemotherapy-based induction and consolidation therapy, together with hematopoietic stem cell transplantation. However, not all patients are eligible for intensive therapy, which can be both physically and mentally demanding, and this approach is more frequently used in healthy, younger patients. Since 2017 the US Food and Drug Administration (FDA) has approved glasdegib, venetoclax, ivosidenib, midostaurin, CPX- 351, and gemtuzumab ozogamicin (GO) to treat persons with newly diagnosed acute myeloid leukemia. The European Medicines Agency (EMA) has done likewise for midostaurin, CPX-351, and GO.
Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a major concern. The intensive chemotherapy treatments used for AML have serious
To further improve the treatment scenario, several major pharma and biotech companies are developing Acute Myeloid Leukemia therapies. Currently, Gamida Cell is leading the therapeutics market with its Acute Myeloid Leukaemia drug candidates in the most advanced stage of clinical development.
Acute Myeloid Leukemia Companies Actively Working in the Therapeutics Market Include
Abbvie, Actinium Pharmaceuticals, Agastiya Biotech, AGC Biologics S.p.A., Agios Pharmaceuticals, Allogene therapeutics, Aprea Therapeutics, Aptevo Therapeutics, Armaceutica, Arog Pharmaceuticals, Astellas Pharma, Astex Pharmaceuticals, Inc., AstraZeneca, Bellicum Pharmaceuticals, BerGenBio ASA, Bio-Path Holdings, Biosight Ltd., Bristol-Myers Squibb, Cardiff Oncology, Celgene, CellCentric Ltd., Chimerix, Clear Creek Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Curis, Inc., Daiichi Sankyo., DCPrime BV, Delta-Fly Pharma, Forma Therapeutics, GEMoaB Monoclonals, Gilead Sciences, GlycoMimetics, GlycoMimetics Incorporated, GT Biopharma, Inc., Hanmi Pharmaceutical Company Limited, Immune-Onc Therapeutics, Immunicum, ImmunityBio, ImmunoGen, Inc., Immunomedics, Inc., Incyte Corporation, Janssen Research & Development, LLC, Jasper Therapeutics, Jazz Pharmaceuticals, Kronos Bio, MacroGenics, MediGene, Molecular Partners, New Epsilon Innovation Limited, NexImmune Inc., Novartis, Oncoceutics, Orca Bio, PersonGen BioTherapeutics, Pfizer, Poseida Therapeutics, Precigen, Inc., Rafael Pharmaceuticals Inc., Sellas Life Sciences Group, Sumitomo Dainippon Pharma Co., Ltd., Syndax Pharmaceuticals, Synimmune GmbH, Syros Pharmaceuticals, Takeda Oncology, TC BioPharm, Teva Pharmaceutical Industries, Xencor, Inc., and others.
Emerging and Marketed Acute Myeloid Leukemia Therapies Covered in the Report Include:
-
Omidubicel: Gamida Cell
-
Uproleselan: GlycoMimetics
-
ALT 803: ImmunityBio
-
BPX-501: Bellicum Pharmaceuticals
-
Dociparstat Sodium (Chimerix Pharmaceuticals)
-
Crenolanib besylate: Arog pharmaceuticals
-
JSP191: Jasper Therapeutics
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Myeloid Leukemia Competitive Intelligence Analysis
4. Acute Myeloid Leukemia Market Overview at a Glance
5. Acute Myeloid Leukemia Disease Background and Overview
6. Acute Myeloid Leukemia Patient Journey
7. Acute Myeloid Leukemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Myeloid Leukemia Unmet Needs
10. Key Endpoints of Acute Myeloid Leukemia Treatment
11. Acute Myeloid Leukemia Marketed Therapies
12. Acute Myeloid Leukemia Emerging Drugs and Latest Therapeutic Advances
13. Acute Myeloid Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Acute Myeloid Leukemia Market Outlook (In US, EU5, and Japan)
16. Acute Myeloid Leukemia Companies Active in the Market
17. Acute Myeloid Leukemia Access and Reimbursement Overview
18. KOL Views on the Acute Myeloid Leukemia Market
19. Acute Myeloid Leukemia Market Drivers
20. Acute Myeloid Leukemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Marginal Zone Lymphoma market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices